Pioneering the development of next-generation oral immunotherapies

• CHAIN is developing novel oral immunotherapies against epithelial cancers using its proprietary bacterial-based technology (CADD).
• Introduction and application of CADD: engineering non-pathogenic Clostridium butyricum for precise, oral delivery of antigens, directly targeting mucosal linings for a safe and durable response
• Validation and refinement of the CADD technology to date; plans and challenges associated with developing LBPs

Speakers:

Jess tyson

Project Manager, Research

CHAIN Biotechnology Ltd